OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
30/07/2026
Voltar para busca
Dado oficial do USPTO
CYCURIA
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
25
Atualização mais recente
30/07/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 42
Data de depósito
12/11/2024
Data de registro
10/03/2026
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
10/03/2026
Última transação
30/07/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
99
Localização do titular
AT
Examinador
KAPLAN, VALERIE ELIZABETH
Unidade examinadora
L70
Localização atual
FILE REPOSITORY (FRANCONIA)
Titulares e representantes
Titulares
Cycuria Therapeutics GmbH
Cycuria GmbH
Representantes
Alisa C. Simmons Fitch Even Tabin & Flannery LLP
Classificação técnica
Classes Nice
Classe 5Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparations and formulationsmedicated health preparationsfor use in the treatment or prevention of human and animal diseasesdisorders and conditionsespecially circulatoryrespiratoryendocrineneurologiccardiovascularalimentarypulmonarymusculoskeletallymphatic and gastrointestinal diseasesdisorders and conditionsthe treatment or prevention of complications associated with such diseasesdisorders and conditions; pharmaceutical preparations and formulationsmedicated health preparationsfor use in the treatment or prevention of human and animal diseasesdisorders and conditionsespecially bone sensoryviralurinaryrenalmetabolic and central nervous system diseasesdisorders and conditionsthe treatment or prevention of complications associated with such diseasesdisorders and conditions; pharmaceutical preparations and formulationsmedicated health preparationsfor use in the treatment or prevention of human and animal diseasesdisorders and conditionsespecially infectiousauto-immune and immune-relatedcell-proliferative and oncologic diseasesdisorders and conditionscancerstumours and metastasesthe treatment or prevention of complications associated with such diseasesdisorders and conditions; diagnostic preparations and biomarker reagents for medical or veterinary purposes; diagnostic preparations and biomarker reagents for the diagnosis and prognosis of human and animal diseasesdisorders and conditionsespecially circulatoryrespiratoryendocrineneurologiccardiovascularalimentarypulmonarymusculoskeletallymphatic and gastrointestinal diseasesdisorders and conditionsthe diagnosis and prognosis of complications associated with such diseasesdisorders and conditions; diagnostic preparations and biomarker reagents for the diagnosis and prognosis of human and animal diseasesdisorders and conditionsespecially bone sensoryviralurinaryrenalmetabolic and central nervous system diseasesdisorders and conditionsthe diagnosis and prognosis of complications associated with such diseasesdisorders and conditions; diagnostic preparations and biomarker reagents for the diagnosis and prognosis of human and animal diseasesdisorders and conditionsespecially infectiousauto-immune and immune-relatedcell-proliferative and oncologic diseasesdisorders and conditionscancerstumours and metastasesthe diagnosis and prognosis of complications associated with such diseasesdisorders and conditions.
Classe 42
Scientific services and research relating theretoscientific research; Scientific services and research relating theretoscientific research and development; Scientific services and research relating theretoscientific research for medical purposes in the field of cancerous diseases; Scientific services and research relating theretoscientific researchanalysistesting in the fields of genomicsgeneticsgenetic engineeringbiotechnologymedicine; Scientific services and research relating theretoproviding scientific research information in the field of genetics; Scientific services and research relating theretoproviding scientific research information in the field of pharmaceuticals; Scientific services and research relating theretoscientific laboratory services; Scientific services and research relating theretoscientific research and scientific research information in the field of pharmaceuticals and clinical trials and conducting clinical trials for others; scientific services and research relating theretoscientific researchscientific research and developmentanalysistestingproviding of scientific research information in the fields of biologychemistry or medicineas well as in the fields of immunologyoncologymolecular biologycellular biologybiochemistry and medicinal chemistry as well as in the fields of discovery and development of pharmaceuticalsmedical and veterinary preparationsdiagnostic preparations and biomarker reagents and diagnostic apparatus; scientific services and research theretoscientific researchscientific research and developmentanalysistestingproviding of scientific research information in the field of discovery of drug targets and drug candidates for the treatment or diagnostics of diseasesdisorders and conditions in humans and animalsin particular in the fields of oncologyinflammatory-autoimmune- and metabolic diseases; providing technical and scientific information about a biotechnology companyits technologiesprojectsproduct-candidatesproducts and services via a web site on a global computer network; design and development of computer software; design and development of computer software for use in the fields of biologychemistry or medicineespecially immunologyoncologymolecular biologycellular biologybiochemistry and/or medicinal chemistryas well as in the fields of discovery and development of pharmaceuticalsmedical and veterinary preparationsdiagnostic preparations and biomarker reagents and diagnostic apparatus.
Publicações
Histórico de despachos e eventos da marca no USPTO.
25 publicações encontradas
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
13/07/2026
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
12/07/2026
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
10/06/2026
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
10/03/2026
R.PR
REGISTERED-PRINCIPAL REGISTER
10/03/2026
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
20/01/2026
PUBO
PUBLISHED FOR OPPOSITION
20/01/2026
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
14/01/2026
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
20/12/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
19/12/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
19/12/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
19/12/2025
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
28/08/2025
CORR
CORRECTION FROM IB ENTERED - NO REVIEW REQUIRED
12/08/2025
RFNT
REFUSAL PROCESSED BY IB
12/07/2025
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
22/06/2025
RFRR
REFUSAL PROCESSED BY MPU
22/06/2025
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
24/04/2025
CNRT
NON-FINAL ACTION WRITTEN
23/04/2025
DOCK
ASSIGNED TO EXAMINER
15/04/2025
CRCV
CORRECTION TRANSACTION RECEIVED FROM IB
14/02/2025
MAFR
APPLICATION FILING RECEIPT MAILED
27/12/2024
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
27/12/2024
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
26/12/2024
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace CYCURIA ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.